Seungjoon Oh

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52-week, multicentre, randomized, placebo-controlled, phase III clinical trial.

Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52-week, multicentre, randomized, placebo-controlled, phase III clinical trial.

Journal: Diabetes, obesity & metabolism

Published: May 08, 2025

Effects of Physical Activity on Medical Expenses among Individuals with Obesity in Korea: Insights from a Nationwide Study.

Effects of Physical Activity on Medical Expenses among Individuals with Obesity in Korea: Insights from a Nationwide Study.

Journal: Journal of obesity & metabolic syndrome

Published: February 12, 2025

Redefining the limits of actuating fibers via mesophase control: From contraction to elongation.

Redefining the limits of actuating fibers via mesophase control: From contraction to elongation.

Journal: Science advances

Published: January 17, 2025

Long-term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52-week extension of a Phase 3 randomized controlled trial.

Long-term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52-week extension of a Phase 3 randomized controlled trial.

Journal: Diabetes, obesity & metabolism

Published: March 08, 2024

A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.

A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.

Journal: Diabetes, obesity & metabolism

Published: November 13, 2023

Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: Results of a 12-week, multicentre, randomized, double-blind, placebo-controlled, phase 2 trial.

Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: Results of a 12-week, multicentre, randomized, double-blind, placebo-controlled, phase 2 trial.

Journal: Diabetes, obesity & metabolism

Published: December 20, 2022

Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial.

Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial.

Journal: Diabetes, obesity & metabolism

Published: December 08, 2022

Diagnosis and Treatment of Growth Hormone Deficiency: A Position Statement from Korean Endocrine Society and Korean Society of Pediatric Endocrinology.

Diagnosis and Treatment of Growth Hormone Deficiency: A Position Statement from Korean Endocrine Society and Korean Society of Pediatric Endocrinology.

Journal: Endocrinology and metabolism (Seoul, Korea)

Published: February 04, 2020

Tetrabromobisphenol A Promotes the Osteoclastogenesis of RAW264.7 Cells Induced by Receptor Activator of NF-kappa B Ligand In Vitro.

Tetrabromobisphenol A Promotes the Osteoclastogenesis of RAW264.7 Cells Induced by Receptor Activator of NF-kappa B Ligand In Vitro.

Journal: Journal of Korean medical science

Published: June 19, 2019

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement.

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement.

Journal: Endocrinology and metabolism (Seoul, Korea)

Published: November 22, 2018

Cardio-Ankle Vascular Index as a Surrogate Marker of Early Atherosclerotic Cardiovascular Disease in Koreans with Type 2 Diabetes Mellitus.

Cardio-Ankle Vascular Index as a Surrogate Marker of Early Atherosclerotic Cardiovascular Disease in Koreans with Type 2 Diabetes Mellitus.

Journal: Diabetes & metabolism journal

Published: November 21, 2017

Tetrabromobisphenol A induces cellular damages in pancreatic β-cells in vitro.

Tetrabromobisphenol A induces cellular damages in pancreatic β-cells in vitro.

Journal: Journal of environmental science and health. Part A, Toxic/hazardous substances & environmental engineering

Published: March 17, 2017

Showing 1-12 of 32

Last Updated: 09/26/2026